Interferon alfa and antiretroviral agents: A treatment option for adult T-cell leukemia/lymphoma

Drugs of Today

Volumn 47, Issue 8, 2011, Pages 615-623

  Ishitsuka, Kenji ^a,c   Tsukasaki, K ^b,c   Tamura, K ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG)   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; DRUG METABOLITE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; METHOTREXATE; RECOMBINANT ALPHA INTERFERON; TELOMERASE; TRANSCRIPTION FACTOR REL; UNCLASSIFIED DRUG; ZIDOVUDINE; ZIDOVUDINE TRIPHOSPHATE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG FEVER; DRUG MECHANISM; ENZYME INHIBITION; ERYTHROCYTE TRANSFUSION; FATIGUE; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; INFECTION; KAPOSI SARCOMA; KIDNEY CARCINOMA; LEUKEMIA REMISSION; LYMPHOCYTOMA; LYMPHOMA; MACROPHAGE; MULTIPLE MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PRIMARY EFFUSION LYMPHOMA; PROGNOSIS; REVIEW; SIDE EFFECT; SURVIVAL TIME; T CELL LEUKEMIA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HUMANS; INTERFERON-ALPHA; LEUKEMIA-LYMPHOMA, ADULT T-CELL; ZIDOVUDINE;

EID: 80052770979     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.8.1590785     Document Type: Review

References (58)

1. Shimoyama, M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991, 79(3): 428-37.
2. Shimoyama, M. Chemotherapy of ATL. In: Adult T-Cell Leukemia. K. Takatsuki (Ed.). Oxford University Press: Oxford 1994, 221-37.
3. Tsukasaki, K., Hermine, O., Bazarbachi, A. et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009, 27(3): 453-9.
4. Yamada, Y., Tomonaga, M., Fukuda, H. et al. A new G-CSFsupported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001, 113(2): 375-82.
5. Tsukasaki, K., Utsunomiya, A., Fukuda, H. et al. VCAP-AMPVECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007, 25(34): 5458-64.
6. Fukushima, T., Miyazaki, Y., Honda, S. et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/ lymphoma. Leukemia 2005, 19(5): 829-34.
7. Hishizawa, M., Kanda, J., Utsunomiya, A. et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010, 116(8): 1369-76.
8. Okamura, J., Utsunomiya, A., Tanosaki, R. et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult Tcell leukemia/lymphoma. Blood 2005, 105(10): 4143-5.
9. Tanosaki, R., Uike, N., Utsunomiya, A. et al. Allogeneic hematopoietic stem cell transplantation using reducedintensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant 2008, 14(6): 702-8.
10. Choi, I., Tanosaki, R., Uike, N. et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials. Bone Marrow Transplant 2011, 46(1): 116-8.
11. Gill, P.S., Harrington, W., Jr., Kaplan, M.H. et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995, 332(26): 1744-8.
12. Hermine, O., Bouscary, D., Gessain, A. et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995, 332(26): 1749-51.
13. Hermine, O., Allard, I., Levy, V., Arnulf, B., Gessain, A., Bazarbachi, A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002, 3(6): 276-82.
14. Matutes, E., Taylor, G.P., Cavenagh, J. et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 2001, 113(3): 779-84.
15. White, J.D., Wharfe, G., Stewart, D.M. et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 2001, 40(3-4): 287-94.
16. Ramos, J.C., Ruiz, P., Jr., Ratner, L. et al. IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood 2007, 109(7): 3060-8.
17. Ishitsuka, K., Katsuya, H., Toyota, T. et al. Interferon-alpha and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: case reports of Japanese patients. Int J Hematol 2010, 92(5): 762-4.
18. Bazarbachi, A., Plumelle, Y., Carlos Ramos, J. et al. Metaanalysis on the use of Zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 2010, 28(27): 4177-83.
19. Bazarbachi, A., Ghez, D., Lepelletier, Y., Nasr, R., de The, H., El-Sabban, M.E., Hermine, O. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol 2004, 5(11): 664-72.
20. Ishitsuka, K., Fukushima, T., Tsukasaki, K., Tobinai, K. Is Zidovudine and interferon-alfa the gold standard for adult Tcell leukemia-lymphoma? J Clin Oncol 2010, 28(36): e765.
21. Yamada, Y. [High-risk aggressive lymphoma (ATL)]. Rinsho Ketsueki 2001, 42(4): 293-8.
22. Takasaki, Y., Iwanaga, M., Imaizumi, Y. et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 2010, 115(22): 4337-43.
23. Bazarbachi, A., Nasr, R., El-Sabban, M.E. et al. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia 2000, 14(4): 716-21.
24. Kirkwood, J.M., Ernstoff, M.S. Interferons in the treatment of human cancer. J Clin Oncol 1984, 2(4): 336-52.
25. Roth, M.S., Foon, K.A. Alpha interferon in the treatment of hematologic malignancies. Am J Med 1986, 81(5): 871-82.
26. Uchida, N., Otsuka, T., Arima, F. et al. Correlation of telomerase activity with development and progression of adult Tcell leukemia. Leuk Res 1999, 23(3): 311-6.
27. Sinha-Datta, U., Horikawa, I., Michishita, E. et al. Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cells. Blood 2004, 104(8): 2523-31.
28. Kubuki, Y., Suzuki, M., Sasaki, H. et al. Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk Lymphoma 2005, 46(3): 393-9.
29. Xu, D., Erickson, S., Szeps, M. et al. Interferon alpha downregulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 2000, 96(13): 4313-8.
30. Furman, P.A., Fyfe, J.A., St Clair, M.H. et al. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1986, 83(21): 8333-7.
31. Copeland, W.C., Chen, M.S., Wang, T.S. Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA. J Biol Chem 1992, 267(30): 21459-64.
32. Strahl, C., Blackburn, E.H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996, 16(1): 53-65.
33. Mo, Y., Gan, Y., Song, S., Johnston, J., Xiao, X., Wientjes, M.G., Au, J.L. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003, 63(3): 579-85.
34. Brown, T., Sigurdson, E., Rogatko, A., Broccoli, D. Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann Surg Oncol 2003, 10(8): 910-5.
35. Savaraj, N., Wu, C., Wangpaichitr, M. et al. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int J Oncol 2003, 23(1): 173-9.
36. Falchetti, A., Franchi, A., Bordi, C. et al. Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J Bone Miner Res 2005, 20(3): 410-8.
37. Ji, H.J., Rha, S.Y., Jeung, H.C., Yang, S.H., An, S.W., Chung, H.C. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Breast Cancer Res Treat 2005, 93(3): 227-36.
38. Datta, A., Bellon, M., Sinha-Datta, U. et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53- dependent senescence. Blood 2006, 108(3): 1021-9.
39. Datta, A., Nicot, C. Telomere attrition induces a DNA doublestrand break damage signal that reactivates p53 transcription in HTLV-I leukemic cells. Oncogene 2008, 27(8): 1135-41.
40. Tawara, M., Hogerzeil, S.J., Yamada, Y. et al. Impact of p53 aberration on the progression of adult T-cell leukemia/ Lymphoma. Cancer Lett 2006, 234(2): 249-55.
41. Matsushita, S., Mitsuya, H., Reitz, M.S., Broder, S. Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I. J Clin Invest 1987, 80(2): 394-400.
42. Macchi, B., Faraoni, I., Zhang, J., Grelli, S., Favalli, C., Mastino, A., Bonmassar, E. AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. J Gen Virol 1997, 78(Pt. 5): 1007-16.
43. Balestrieri, E., Forte, G., Matteucci, C., Mastino, A., Macchi, B. Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro. Antimicrob Agents Chemother 2002, 46(9): 3080-3.
44. Garcia-Lerma, J.G., Nidtha, S., Heneine, W. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine. J Infect Dis 2001, 184(4): 507-10.
45. Machuca, A., Rodes, B., Soriano, V. The effect of antiretroviral therapy on HTLV infection. Virus Res 2001, 78(1-2): 93-100.
46. Taylor, G.P., Goon, P., Furukawa, Y. et al. Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial. Retrovirology 2006, 3: 63.
47. Harrington, W.J., Jr., Cabral, L., Cai, J.P., Chan, A.S.S., Wood, C. Azothymidine and interferon-alpha are active in AIDSassociated small non-cleaved cell lymphoma but not largecell lymphoma. Lancet 1996, 348(9030): 833.
48. Tosi, P., Gherlinzoni, F., Mazza, P. et al. 3'-Azido 3'- deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virusrelated non-Hodgkin's lymphomas. Blood 1997, 89(2): 419-25.
49. Langford, A., Ruf, B., Kunze, R., Pohle, H.D., Reichart, P. Regression of oral Kaposi's sarcoma in a case of AIDS on zidovudine (AZT). Br J Dermatol 1989, 120(5): 709-13.
50. Oksenhendler, E., Clauvel, J.P., Jouveshomme, S., Davi, F., Mansour, G. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol 1998, 57(3): 266.
51. Roychowdhury, S., Peng, R., Baiocchi, R.A. et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 2003, 63(5): 965-71.
52. Kurokawa, M., Ghosh, S.K., Ramos, J.C. et al. Azidothymidine inhibits NF-kappaB and induces Epstein- Barr virus gene expression in Burkitt lymphoma. Blood 2005, 106(1): 235-40.
53. Alizadeh, A.A., Bohen, S.P., Lossos, C. et al. Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha. Leuk Lymphoma 2010, 51(7): 1200-16.
54. Ishitsuka, K., Ikeda, S., Utsunomiya, A. et al. Smouldering adult T-cell leukaemia/lymphoma: a follow-up study in Kyushu. Br J Haematol 2008, 143(3): 442-4.
55. Ikeda, S., Momita, S., Kinoshita, K. et al. Clinical course of human T-lymphotropic virus type I carriers with molecularly detectable monoclonal proliferation of T lymphocytes: defining a low- and high-risk population. Blood 1993, 82(7): 2017-24.
56. Kchour, G., Tarhini, M., Kooshyar, M.M. et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113(26): 6528-32.
57. Yamamoto, K., Utsunomiya, A., Tobinai, K. et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010, 28(9): 1591-8.
58. Ishitsuka, K., Tamura, K. Treatment of adult T-cell leukemia/lymphoma: past, present and future. Eur J Haematol 2008, 80(3): 185-96.